Article Text

Download PDFPDF

OP0106 Who is not reaching remission in early ra and why? predictors for persistent disease activity in the first year differ in men and women and are related to lifestyle and treatment
  1. S.J Bartlett1,2,
  2. O. Schieir3,
  3. M.-F. Valois4,
  4. C. Hitchon5,
  5. G. Boire6,
  6. B. Haraoui7,
  7. C. Thorne8,
  8. D. Tin8,
  9. J. Pope9,
  10. E.C. Keystone3,10,
  11. V.P. Bykerk3,11,
  12. on behalf of on behalf of CATCH (Canadian Early Arthritis Cohort) Investigators
  1. 1Medicine/ClinEpi and Rheumatology, McGill University, Montreal, QC, Canada
  2. 2Medicine/Rheumatology, Johns Hopkins, Baltimore, USA
  3. 3University of Toronto, Toronto, ON
  4. 4Clinical Epidemiology, McGill University, Montreal, QC
  5. 5Rheumatology, University of Manitoba, Winnipeg, MB
  6. 6Rheumatologie, Universite de Sherbrooke, Sherbrooke, QC
  7. 7Institute de Rheumatologie, Montreal, QC
  8. 8Southlake Regional Health Centre, Newmarket, ON
  9. 9Western University, London, ON
  10. 10Sinai Health System, Toronto, ON, Canada
  11. 11Hospital for Special Surgery, New York, NY, USA

Abstract

Background Although early identification and aggressive treatment of RA improves outcomes, we have shown that 45% of early RA participants receiving guideline-based care do not achieve remission in the first year. Moreover, fewer women reached remission than men.

Objectives To compare predictors of persistent disease activity (LDA/MDA/HAD) in the 1 st year of RA treatment in men and women.

Methods Sample included adults in CATCH (Canadian Early Arthritis Cohort) from 2007–2016 with active disease at baseline and ≥12 m F/U. Standardised visits included clinical assessments, questionnaires, and lab tests. Logistic regression with backward selection was used to identify predictors of failing to achieve remission (DAS28 <2.6) by 12 months among baseline sociodemographic and RA characteristics and patient reported outcomes.

Results The sample included 1628 adults with classifiable RA, who were mostly female (72%) with a mean (SD) age of 55, (15) with 2 (2) comorbidities, and symptom duration of 6 (3) months. At enrollment, 95% had active disease (DAS28 MDA (42%); HDA (53%)), most were initially treated with csDMARDS (any 92%; MTX 75%). 46% of women and 38% of men did not reach remission by 12 months. Among women, multivariable results showed obesity more than doubled the likelihood of not achieving remission; other key predictors were minority status, lower education, and higher TJC and fatigue scores at baseline (table 1). In men, current smoking was associated with a 3.5 greater odds of not achieving remission in the first year; other predictors included older age, and higher pain. Not using MTX increased the likelihood of not achieving remission in women by 28% and men by 45%. Longer symptom duration and higher ESR were associated with not achieving remission in all. Factors not related to persistent disease activity included family history of RA, RF/ACPA status, erosions, SJC, HAQ and depressive symptoms at baseline.

Abstract OP0106 – Table 1

Conclusions In this large pan-Canadian cohort of early RA patients receiving guideline-based arthritis care, obesity in women and current smoking in men were the strongest predictors of not achieving remission in the first 12 months followed by non-use of MTX, higher baseline inflammation and longer symptom duration. Additional poor prognostic indicators in women included minority status, lower education, and higher fatigue, whereas older age and greater pain were associated with persistent disease activity in men. Smoking cessation in men and weight reduction in women, and optimising MTX use may facilitate rapid reduction of inflammation, an essential goal of treatment in early RA.

Acknowledgements Sponsors: Amgen & Pfizer-Founding sponsors 2007+; UCB, AbbVie 2011+; Medexus 2013+; Eli Lilly, Sanofi- Genzyme 2016+; Merck 2017+; BMS 2011–2014, Hoffmann-LaRoche, Janssen 2011–2016

Disclosure of Interest None declared

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.